Novadaq Technologies Inc.TSX: NDQ

Novadaq reports financial results for first quarter of 2006

· Issued by Novadaq Technologies Inc. via CNW
TORONTO, May 8 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ), a
developer of medical imaging systems for the operating room, today reported
its results for the first quarter ended March 31, 2006.
"Novadaq's technology is continuing to gain recognition as the logical
technology platform for imaging in the operating room," said Arun Menawat,
President and CEO of Novadaq Technologies Inc. "The SPY(R) System is the first
commercial implementation of the technology and we are pleased with the
progress made so far in terms of growing sales in the United States. During
the first quarter we also made significant progress in developing a tangible
product pipeline which may allow us to significantly expand our market
opportunity by applying the technology to other markets including
Ophthalmology and Urology."

Selected First Quarter, 2006 Financial and Operating Highlights

-   SPY (Cardiac): 30 SPY systems placed in the United States as of
    March 31, 2006, up from 20 systems at the end of December 2005.
    Procedure based revenues in the first quarter of 2006 more than
    doubled from the previous quarter as adoption of the SPY system in
    cardiac surgery in the United States continues to increase.
    36 SPY systems placed in the United States as at May 1, 2006.
-   OPTTX(R) (Ophthalmology): On track to file for CE Mark approval in
    the second quarter and to begin a limited launch of the product in
    Europe in the second half of 2006. Hired new general manager from a
    leading ophthalmology company to commercialize the OPTTX system.
    Renegotiated licenses with Johns Hopkins University to eliminate
    future license payments, reduce minimum royalty obligations, and
    clarify running royalty obligations.
-   LUNA(TM) (Urology): Licensed Intellectual Property from the
    University of Rochester that enables visualization of nerves and
    lymphatics during urological procedures including prostate surgery.

Financial Results

Revenue increased to approximately $518,000 in Q1-2006 from approximately
$156,000 in Q1-2005. The increase reflects an increase in both procedure based
revenue and capital sales revenue. Procedure based revenue increased due to
the launch of SPY in the US in the first half of 2005. The fourth quarter of
2004 ("Q4-2005") was the first full quarter of sales activities by Sorin, and
procedure based revenue more than doubled in Q1-2006 from Q4-2005.
Capital sales revenue also increased to approximately $189,000 in Q1-2006
from approximately $135,000 in Q1-2005, despite a decision made to move to a
blended procedure/capital sale model in Japan. Whereas SPY imaging systems are
fully financed by the Company in the US, in Japan, the blended model allowed
for the recovery of the manufacturing cost of the imaging systems plus a small
margin. In Q1-2006 six imaging systems were sold under this model, versus
one Imaging System sold in Q1-2005. The move to a blended business model in
Japan is expected to contribute to the Company's recurring revenue stream.
Gross profit increased to approximately $137,000 in Q1-2006 from
approximately $119,000 in Q1-2005, although gross profit as a percentage of
sales decreased as a result of the use of a blended procedure/capital model in
Japan. Gross profit decreased as a percentage of sales from 34% in Q4-2005
to 26% in Q1-2006 as a result of lower margins on capital sales to Japan.
Sales and marketing expenses increased by approximately $559,000 to
approximately $661,000 in Q1-2006 from approximately $102,000 in Q1-2005 when
the SPY System had not been cleared to be marketed in the US. Sales and
marketing expenses also increased from Q4-2005 to Q1-2006 because additional
clinical educators were hired in 2006. Sales and Marketing expenses are
expected to continue to increase moderately during 2006 as the Company
continues to build its team of clinical educators and other internal
resources.
Research and development expenses increased by approximately $664,000 to
approximately $1,383,000 in Q1-2006 from approximately $719,000 in Q1-2005.
The overall increase relates primarily to increases in employee and related
office and travel costs for additional engineering staff to support the OPTTX
design efforts and to support commercial manufacturing of SPY, and additional
clinical staff to plan and execute OPTTX trials. The increase also related to
increased costs incurred to design and build next generation OPTTX devices for
use in clinical trials and an increase in SPY product development costs.
Research and development costs also increased from Q4-2005 to Q1-2006
primarily due to increased patent costs associated with expanding the
company's intellectual portfolio to cover new areas including urological
applications such as nerve sparing radical prostatectomy. Research and
development costs are expected to continue to increase moderately during 2006
to support the patient registry and product development initiatives for SPY
and clinical trials for OPTTX and LUNA.
General and administration expenses increased by approximately $134,000
to approximately $568,000 in Q1-2006 from $434,000 in Q1-2005. This increase
includes increases totaling approximately $254,000 relating to additional
employee costs to support the commercial launch of SPY and public company
costs, offset partially by a decrease stock based compensation expense of
approximately $120,000. The decrease in stock based compensation expense
resulted primarily from the contractual vesting of all options issued prior to
2005 upon the completion of the Company's initial public offering in
June 2005. General and administrative costs decreased by approximately
$126,000 from Q4-2005 to Q1-2006 primarily as a result of a reduction in
professional fees and reduced travel expenses.
Depreciation expense increased to approximately $36,000 in Q1-2006 from
approximately $8,000 in Q1-2005 primarily as a result of additional SPY
devices being used in research and development activities and due to
additional computer hardware, software and other office equipment to support
the growth of the Company's infrastructure. Amortization increased by slightly
from Q1-2005 to Q1-2006 as a result of license payments made in June 2005
which are capitalized and amortized.
The Company had a total investment return of approximately $246,000 in 
Q1-2006 on its cash and short-term investments, including interest income of
approximately $185,000, and other income of approximately $61,000 earned on
money market funds. The increase in investment returns over Q1-2005 is the
result of an overall increase in cash and short term investment balances
following completion of the Company's initial public offering on June 10,
2005, and higher interest rates.
Net loss increased by approximately $1,153,000 to approximately
$2,375,000 in Q1-2006 from approximately $1,222,000 in Q1-2005 primarily as a
result of an increase in sales and marketing costs of approximately $559,000,
an increase in research and development expenses of approximately $664,000, an
increase in general and administrative expenses of approximately $134,000,
offset partially by an increase in investment returns of approximately
$202,000.
As at March 31, 2006 the Company had cash, cash equivalents and     
short-term investments of approximately $25,296,000, an increase of
approximately $2,522,000 over December 31, 2005. The increase in these
balances was primarily the result of the exercise of warrants and special
options in March 2006 for proceeds of approximately $5,429,000 and employee
stock options for proceeds of $2,500 offset by cash used in operations of
2,056,000 and cash invested in property and equipment and licenses of $853,000
during the Q1-2006.
The Company is authorized to issue an unlimited number of common shares
and an unlimited number of preferred shares, issuable in series. As at
March 31, 2006 there were a total of 19,680,276 common shares (21,290,622 on a
fully diluted basis) and no preferred shares outstanding. As at March 31, 2006
a total of 1,610,346 stock options were outstanding under the Company's
employee stock option plan. Additional information concerning the Company,
including its Annual Information Form for the year ended December 31, 2005, is
available on SEDAR at www.sedar.com.

Conference call
Novadaq will host a conference call and live webcast on Monday, May 8,
2006 at 4:30 p.m. E.T. to discuss its first quarter 2006 results. To access
the conference call by telephone, dial 416-644-3427 or 1-800-814-4857. Please
connect approximately ten minutes prior to the beginning of the call to ensure
participation. The conference call will be archived for replay until May 15,
2006 at midnight. To access the archived conference call, dial 416-640-1917 or
1-877-289-8525 and enter the reservation number 21187061 followed by the
number sign.

About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular, ophthalmic, and neurologic diseases and
conditions. Novadaq's SPY Intra-operative Imaging System, commercially
available worldwide, enables cardiac surgeons to visually assess coronary
vasculature and bypass graft functionality during the course of open-heart
bypass surgery. Novadaq's ophthalmic product, the OPTTX System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials. Novadaq's product for nerve visualization in prostate surgery,
LUNA(TM) is designed to enable surgeons to visualize nerve bundles during the
course of radical prostatectomy in order to reduce negative outcomes including
impotency. For more information, please visit the company's website at
www.novadaq.com.

This press release contains certain information that may constitute
forward-looking information within the meaning of securities laws. In some
cases, forward-looking information can be identified by the use of terms such
as "may", "will", "should", "expect", "plan", "anticipate", "believe",
"intend", "estimate", "predict", "potential", "continue" or other similar
expressions concerning matters that are not historical facts. Forward-looking
information may relate to management's future outlook and anticipated events
or results, and may include statements or information regarding the future
financial position, business strategy and strategic goals, research and
development activities, projected costs and capital expenditures, financial
results, research and clinical testing outcomes, taxes and plans and
objectives of or involving Novadaq. Particularly, information regarding future
sales and marketing activities, future revenues and research and development
activities, as well as the Company's plans for each of the SPY System and the
OPTTX System, and the potential for development of an application for the
Company's imaging device in image guided conventional and minimally invasive
nerve-sparing radical prostatectomy, is forward-looking information.
Forward-looking information is based on certain factors and assumptions
regarding, among other things, market acceptance and the rate of market
penetration of Novadaq's SPY System, the clinical results of the use of the
SPY System, the results from clinical tests of the OPTTX System, and potential
opportunities in the AMD treatment market and in image guided conventional and
minimally invasive urological applications including nerve-sparing radical
prostatectomy. While the Company considers these assumptions to be reasonable
based on information currently available to it, they may prove to be
incorrect.
Forward looking-information is subject to certain factors, including
risks and uncertainties that could cause actual results to differ materially
from what we currently expect. These factors include risks relating to the
transition from research and development activities to commercial activities,
market acceptance and adoption of the SPY System, dependence on key suppliers
for components of the SPY System and the OPTTX System, regulatory and clinical
risks, risks relating to the protection of intellectual property, risks
inherent in the conduct of research and development activities, including the
risk of unfavorable or inconclusive clinical trial outcomes, potential product
liability, competition and the risks posed by potential technological
advances, and risks relating to fluctuations in the exchange rate between the
US dollar and the Canadian dollar.
You should not place undue importance on forward-looking information and
should not rely upon this information as of any other date. While Novadaq may
elect to, Novadaq is under no obligation and does not undertake to update this
information at any particular time.
This press release was prepared from information available to May 1,
2006.

Summary financial statements attached:
For complete financial statements please go to www.sedar.com


<<
                      NOVADAQ TECHNOLOGIES INC.
                Incorporated under the laws of Canada

                           BALANCE SHEETS
                        (expressed in U.S.$)
                              Unaudited

                                                  As at         As at
                                                March 31,    December 31,
                                                  2006          2005
                                                    $             $
-------------------------------------------------------------------------

                               ASSETS
Current
Cash and cash equivalents                          922,237       750,727
Short-term investments                          24,374,119    22,023,536
Accounts receivable                                310,778       233,977
Investment tax credits receivable                   41,165        41,341
Prepaid expenses and other receivables             461,358       553,534
Inventory                                          252,778       410,064
-------------------------------------------------------------------------
Total current assets                            26,362,435    24,013,179
-------------------------------------------------------------------------
Property, plant and equipment, net               1,204,267       464,483
Deferred charges                                     9,320        11,259
Licenses, net                                    2,936,114     3,030,711
-------------------------------------------------------------------------
                                                30,512,136    27,519,633
-------------------------------------------------------------------------
-------------------------------------------------------------------------

                LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities         1,309,754     1,432,560
Current portion of deferred revenue                 28,013        37,351
-------------------------------------------------------------------------
Total current liabilities                        1,337,767     1,469,911
-------------------------------------------------------------------------
Deferred revenue                                    21,789        21,789
-------------------------------------------------------------------------
Total liabilities                                1,359,556     1,491,700
-------------------------------------------------------------------------

Shareholders' equity
Share capital                                   51,687,730    46,255,988
Contributed surplus                              3,479,688     3,411,851
Deficit                                        (26,014,838)  (23,639,801)
-------------------------------------------------------------------------
Total shareholders' equity                      29,152,580    26,028,038
-------------------------------------------------------------------------
                                                30,512,136    27,519,633
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                      NOVADAQ TECHNOLOGIES INC.

                   STATEMENTS OF LOSS AND DEFICIT
                        (expressed in U.S.$,)
                              Unaudited


                                                  Three months ended
                                                       March 31,
                                                  2006          2005
                                                    $             $
-------------------------------------------------------------------------

Revenue                                            518,226       155,418
Cost of sales                                      381,153        36,300
-------------------------------------------------------------------------
Gross profit                                       137,073       119,118
-------------------------------------------------------------------------

Operating expenses
Sales and marketing                                660,909       101,732
Research and development                         1,383,504       718,650
General and administration                         567,505       433,571
Depreciation                                        36,966         8,266
Amortization                                       109,597       105,283
Loss (gain) on foreign exchange                       (442)        7,475
-------------------------------------------------------------------------
                                                 2,758,039     1,374,977
-------------------------------------------------------------------------
Loss before the following                       (2,620,966)   (1,255,859)
Other income                                        60,896             0
Interest income                                    185,033        34,321
-------------------------------------------------------------------------
Net loss for the year                           (2,375,037)   (1,221,538)

Deficit, beginning of period                   (23,639,801)  (16,765,343)
-------------------------------------------------------------------------
Deficit, end of period                         (26,014,838)  (17,986,881)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Basic and diluted loss per share                     (0.13)        (0.08)
-------------------------------------------------------------------------
-------------------------------------------------------------------------


                      NOVADAQ TECHNOLOGIES INC.

                      STATEMENTS OF CASH FLOWS
                        (expressed in U.S.$)
                              Unaudited

                                                  Three months ended
                                                       March 31,
                                                  2006          2005
                                                    $             $
-------------------------------------------------------------------------

OPERATING ACTIVITIES
Net loss for the period                         (2,375,037)   (1,221,538)
Add (deduct) items not involving cash
  Depreciation and amortization                    208,322       116,887
  Stock based compensation                          67,837       160,609
-------------------------------------------------------------------------
                                                (2,098,878)     (944,042)
Net change in non-cash working capital
 balances related to operations                     42,738     1,199,932
-------------------------------------------------------------------------
Cash (used) in operating activities             (2,056,140)      255,890
-------------------------------------------------------------------------

FINANCING ACTIVITIES
Issuance common shares, net                      5,431,742             -
-------------------------------------------------------------------------
Cash provided by financing activities            5,431,742             -
-------------------------------------------------------------------------

INVESTING ACTIVITIES
Purchase of property, plant and equipment         (838,508)      (13,097)
Purchase of licenses                               (15,000)            -
Investments in short-term investments, net      (2,350,582)      (61,791)
-------------------------------------------------------------------------
Cash provided by (used in) investing            (3,204,090)      (74,888)
-------------------------------------------------------------------------

Net increase (decrease) in cash and cash
 equivalents during the period                     171,511       181,002
Cash and cash equiv. beginning of period           750,726       434,380
-------------------------------------------------------------------------
Cash and cash equivalents, end of period           922,237       615,382
-------------------------------------------------------------------------
-------------------------------------------------------------------------

>>

%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Story so far

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases